Hong Kong-Listed Sino Biopharma, AstraZeneca Sign Respiratory Drug Deal Worth up to $1.9 Billion
The deal could bring Sino Biopharmaceutical up to $1.9 billion as AstraZeneca expands its respiratory pipeline with a drug that improved lung function in a phase II trial.
- On Wednesday, AstraZeneca agreed to pay China-based Sino Biopharmaceutical $200 million upfront for global rights, excluding China, to the experimental COPD drug TQC3721.
- A Phase 2 study in China showed TQC3721, a PDE 3/4 inhibitor, "significantly improved lung function and symptoms" compared to a placebo, prompting the licensing deal.
- Simultaneously, Sino signed a separate deal with GSK to manage Chinese distribution for respiratory medicines Trelegy and Anoro, aiming to "further expand patient reach and market penetration."
- Sino is eligible to receive up to $1.9 billion in additional milestones, reflecting AstraZeneca's broader commitment of $15 billion to Chinese drug discovery and manufacturing.
- Nearly 100 cross-border alliances have been announced since early 2025, according to BioPharma Dive data, prompting proposed U.S. legislation and regulatory reforms to curtail these partnerships.
11 Articles
11 Articles
The Biopharmaceutical Sino signed a licensing agreement with AstraZeneca for a treatment of chronic respiratory disease and obtained the marketing rights of two GSK drugs in China, at a time when global pharmacists are increasingly seeking the Chinese market to strengthen their portfolios and sales. Exclusive material for subscribers. To have full access, access the link of the subject and register.
AZ buys ex-China rights to Sino’s COPD drug for $2.1bn - European Biotechnology Magazine
AstraZeneca has moved to strengthen its respiratory pipeline with a late-stage Chinese COPD asset, striking a deal that gives it a lower-cost shot at a market MSD recently entered through its $10bn Verona Pharma acquisition. The post AZ buys ex-China rights to Sino’s COPD drug for $2.1bn appeared first on European Biotechnology Magazine.
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
